jRCT2072210059进行中（未招募）不适用
BSJ017W versus NOAC for Embolic Protection in the Management of Patients with Non-Valvular Atrial Fibrillation (CHAMPION-AF Clinical Trial)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 120
- 主要终点
- occurrence of stroke, cardiovascular death, and systemic embolism
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Prevention Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •The subject is of legal age to participate in the study per the laws of their respective geography
- •The subject has documented non-valvular atrial fibrillation (i.e., atrial fibrillation in the absence of moderate or greater mitral stenosis or a mechanical heart valve)
- •The subject has a calculated CHA2DS2-VASc score of 2 or greater for men and 3 or greater for women
- •The subject is deemed to be suitable for the protocol defined pharmacologic regimens in both the test and control arms
- •The subject or legal representative is able to understand and willing to provide written informed consent to participate in the trial
- •The subject is able and willing to return for required follow-up visits and examinations
排除标准
- •Subjects who are currently enrolled in another investigational study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments
- •The subject requires long-term anticoagulation therapy for reasons other than AF-related stroke risk reduction, for example due to an underlying hypercoagulable state (i.e., even if the device is implanted, the subjects would not be eligible to discontinue OAC due to other medical conditions requiring chronic OAC therapy)
- •The subject is contraindicated or allergic to oral anticoagulation medication and/or aspirin
- •The subject is indicated for chronic P2Y12 platelet inhibitor therapy
- •The subject had or is planning to have any cardiac or non-cardiac intervention or surgical procedure within 30 days prior to or 60 days after implant (including, but not limited to: cardioversion, percutaneous coronary intervention (PCI), cardiac ablation, cataract surgery, etc.)
- •The subject had a prior stroke (of any cause, whether ischemic or hemorrhagic) or transient ischemic attack (TIA) within the 30 days prior to enrollment
- •The subject had a prior major bleeding event per ISTH definition within the 30 days prior to randomization. Lack of resolution of related clinical sequelae or planned and pending interventions to resolve bleeding/bleeding source, are a further exclusion regardless of timing of the bleeding event
- •The subject has an active bleed
- •The subject has a reversible cause of AF or transient AF
- •The subject is absent of a LAA or the LAA is surgically ligated
- •The subject has had a myocardial infarction (MI) documented in the clinical record as either a non-ST elevation MI (NSTEMI) or as an ST-elevation MI (STEMI), with or without intervention, within 30 days prior to enrollment
- •The subject has a history of atrial septal repair or has an ASD/PFO device
- •The subject has an implanted mechanical valve prosthesis in any position
- •The subject has a known contraindication to percutaneous catheterization procedure
- •The subject has a known contraindication to TEE
- •The subject has a cardiac tumor
- •The subject has signs/symptoms of acute or chronic pericarditis.
- •The subject has an active infection
- •There is evidence of tamponade physiology
- •The subject has New York Heart Association Class IV Congestive Heart Failure at the time of enrollment
- •The subject is of childbearing potential and is, or plans to become, pregnant during the time of the study (method of assessment upon study physician's discretion)
- •The subject has a documented life expectancy of less than 3 years
- •Transthoracic Echo Exclusion Criteria
- •The subject has LVEF < 30%
- •The subject has an existing pericardial effusion with a circumferential echo-free space > 5mm
- •The subject has a high-risk patent foramen ovale (PFO) with an atrial septal aneurysm excursion > 15mm or length > 15mm
- •The subject has significant mitral valve stenosis (i.e., MV area < 1.5 cm^2)
结局指标
主要结局
occurrence of stroke, cardiovascular death, and systemic embolism
时间窗: 36-months
BSJ017W is non-inferior (NI) for the occurrence of stroke, cardiovascular death, and systemic embolism
non-procedural bleeding (ISTH major bleeding and clinically relevant non-major bleeding)
时间窗: 36-months
BSJ017W is superior for non-procedural bleeding (ISTH major bleeding and clinically relevant non-major bleeding)
occurrence of ischemic stroke and systemic embolism
时间窗: 60 months
BSJ017W is non-inferior (NI) for the occurrence of ischemic stroke and systemic embolism
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
不适用
PASSAGE Clinical TrialjRCT2032220496Boston Scientific Japan K.K.51
招募中
2 期
Effectiveness of Perilla oil with Mild to Moderate of Dementia PatientDevelopment of the medical and society led to population in the world are long life which rate of height birth in last time relate with be in move to aged elderly. Campaign for control the birth rateDementia,alzheimer's disease,Perilla frutescens (L.) Britton,Omaga3,Clinical Trial,Randomize Control Trial,Cognitive function,MOCATCTR20150914001Agricultural Research Development Agency (Public Organization)234
招募中
3 期
on-inferiority clinical trial to compare efficacy and safety of Pembrolizumab (CinnaGen Co.) versus Keytruda® in patients with metastatic Non-Small Cell Lung Cancer (NSCLC)IRCT20150303021315N29CinnaGen company295
进行中（未招募）
1 期
Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial CarcinomaAdvanced or Metastatic Urothelial CarcinomaMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2015-005731-41-IEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.990
已完成
3 期
A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinomabladder cancerNL-OMON45288Merck Sharp & Dohme (MSD)20